Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAK-242 in adults with severe sepsis
2005-003561-16Phase 3Completed
- Sponsor
- Takeda
- Start
- Oct 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in sepsis comparing TAK-242 with Placebo (2 arms). Primary endpoint: 28-day all-cause mortality. Started Oct 2005; status: completed.
02
Drugs
resatorvid
03
Conditions
sepsis
Beyond the preview
Go deeper on 2005-003561-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-003561-16.